Literature DB >> 32640261

Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat hippocampus.

Mohammed E A Elhussiny1, Giulia Carini1, Jessica Mingardi1, Paolo Tornese2, Nathalie Sala2, Federica Bono3, Chiara Fiorentini3, Luca La Via1, Maurizio Popoli2, Laura Musazzi2, Alessandro Barbon4.   

Abstract

Converging clinical and preclinical evidence has shown that dysfunction of the glutamate system is a core feature of major depressive disorder. In this context, the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine has raised growing interest as fast acting antidepressant. Using the chronic mild stress (CMS) rat model of depression, performed in male rats, we aimed at analyzing whether hippocampal specific changes in subunit expression and regulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or NMDA ionotropic receptors and in metabotropic glutamate receptors could be associated with behavioral vulnerability/resilience to CMS. We also assessed whether acute ketamine (10 mg/kg) was able to dampen the alterations in CMS vulnerable animals. Although chronic stress and ketamine had no effect on ionotropic glutamate receptors mRNAs (expression, RNA editing and splicing), we found selective modulations in their protein expression, phosphorylation and localization at synaptic membranes. AMPA GluA2 expression at synaptic membranes was significantly increased only in CMS resilient rats (although a trend was found also in vulnerable animals), while its phosphorylation at Ser880 was higher in both CMS resilient and vulnerable rats, a change partially dampened by ketamine. In the hippocampus from all stressed groups, despite NMDA receptor expression levels were reduced in total extract, the levels of GluN2B-containing NMDA receptors were remarkably increased in synaptic membranes. Finally, mGlu2 underwent a selective downregulation in stress vulnerable animals, which was completely restored by acute ketamine. Overall, these results are in line with a hypofunction of activity-dependent glutamatergic synaptic transmission induced by chronic stress exposure in all the animals, as suggested by the alterations of ionotropic glutamate receptors expression and localization at synaptic level. At the same time, the selective modulation of mGlu2 receptor, confirms its previously hypothesized functional role in regulating stress vulnerability and, for the first time here, suggests a mGlu2 involvement in the fast antidepressant effect of ketamine.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant; Chronic mild stress; Glutamate receptors; Ketamine; RNA editing; Stress vulnerability

Year:  2020        PMID: 32640261     DOI: 10.1016/j.pnpbp.2020.110033

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

Review 1.  The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders.

Authors:  Gerard Sanacora; Zhen Yan; Maurizio Popoli
Journal:  Nat Rev Neurosci       Date:  2021-12-10       Impact factor: 34.870

2.  Occlusion of dopamine-dependent synaptic plasticity in the prefrontal cortex mediates the expression of depressive-like behavior and is modulated by ketamine.

Authors:  Francesco Isotti; Mattia Ferro; Jacopo Lamanna; Sara Spadini; Gabriella Racchetti; Laura Musazzi; Antonio Malgaroli
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

3.  The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.

Authors:  Melody J Y Kang; Emily Hawken; Gustavo Hector Vazquez
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

Review 4.  Neurobiology of Depression: Chronic Stress Alters the Glutamatergic System in the Brain-Focusing on AMPA Receptor.

Authors:  Ming Tatt Lee; Wei-Hao Peng; Hung-Wei Kan; Cheng-Chun Wu; Deng-Wu Wang; Yu-Cheng Ho
Journal:  Biomedicines       Date:  2022-04-27

5.  An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.

Authors:  Sherry-Anne Muscat; Glenn Hartelius; Courtenay Richards Crouch; Kevin W Morin
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

Review 6.  Genetic variables of the glutamatergic system associated with treatment-resistant depression: A review of the literature.

Authors:  Estela Saez; Leire Erkoreka; Teresa Moreno-Calle; Belen Berjano; Ana Gonzalez-Pinto; Nieves Basterreche; Aurora Arrue
Journal:  World J Psychiatry       Date:  2022-07-19

Review 7.  RNA Editing and Modifications in Mood Disorders.

Authors:  Alessandro Barbon; Chiara Magri
Journal:  Genes (Basel)       Date:  2020-07-31       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.